Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Ano de publicação
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Oncol Rep ; 23(1): 205-10, 2010 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-19956883

RESUMO

Auron-Misheil-Therapy (AMT) is a defined but unique combination of approved pharmaceuticals. It consists of insulin, chlorpheniramine and an aqueous camomile extract, and it has been successfully applied clinically in late-stage cancer patients. The purpose of this study was to elucidate the anti-tumor efficacy of AMT in a validated murine renal cell carcinoma animal model (RENCA). There were two independent studies; each animal group consisted of 16 mice. During a 6-week pretreatment period, vehicle (group A) and AMT (1.6 mg/kg/d) (group B) were administered once daily in a 5 days/week schedule either intramuscularly or subcutaneously. Tumor challenge at day 0 was followed by a 3-week treatment period (either vehicle or AMT once daily intramuscularly for 21 days consecutively). In study 2 the AMT dosage was increased up to 4-fold by doubling individual doses and switching to a twice daily schedule. The injections were all intramuscular. With the exception of group D, a six-week pretreatment period preceded the tumor challenge at day 0. Tumor challenge was followed by a 3-week treatment period (vehicle, AMT at either 3.2 mg/kg/d) (group A) or 6.4 mg/kg/d (group B), or AMT0, an AMT preparation which does not stimulate IL-6 secretion (6.4 mg/kg/d, group C) continuously for 21 days. AMT administration for group D (6.4 mg/kg/d) was limited to the treatment period from day 1 to 21. All mice were sacrificed 21 days after tumour transplantation. AMT administration was safe and well tolerated, and significantly reduced primary tumor volume in pretreated animals. The effective route of application was intramuscular, with dose escalation resulting in an improved anti-tumor effect. This is the first demonstration of a significant anti-tumorigenic effect of AMT in a validated tumor model.


Assuntos
Antineoplásicos/uso terapêutico , Cálcio/uso terapêutico , Carcinoma de Células Renais/tratamento farmacológico , Clorfeniramina/uso terapêutico , Insulina/uso terapêutico , Neoplasias Renais/tratamento farmacológico , Extratos Vegetais/uso terapêutico , Animais , Linhagem Celular Tumoral , Modelos Animais de Doenças , Relação Dose-Resposta a Droga , Ensaios de Seleção de Medicamentos Antitumorais , Feminino , Interleucina-6/metabolismo , Camundongos , Camundongos Endogâmicos BALB C , Transplante de Neoplasias , Fatores de Tempo
2.
Rev. ginecol. obstet ; 7(3): 139-44, jul.-set. 1996. ilus, tab
Artigo em Português | LILACS | ID: lil-186854

RESUMO

Foram avaliadas 379 mulheres com teste de Schiller positivo atendidas pelos Servicos de Tocoginecologia Preventiva e Colposcopia do Centro de Referencia da Saude da Mulher e de Nutricao, Alimentacao e Desenvolvimento Infantil, no periodo de agosto de 1991 a fevereiro de 1994. Em todos os casos foi realizada a colpocitologia oncologica, colposcopia e, quando indicado, estudo histopatologico da cervix...


Assuntos
Humanos , Feminino , Adulto , Colo do Útero , Neoplasias do Colo do Útero/prevenção & controle , Neoplasias Uterinas/prevenção & controle , Colposcopia , Técnicas de Preparação Histocitológica
SELEÇÃO DE REFERÊNCIAS
Detalhe da pesquisa